A Canadian drug company with research facilities in Bucks County expects to begin human testing of four potential hepatitis B treatments during the first half of next year.
Doylestown-based researcher Michael J. Sofia — inventor of Gilead Siences Inc.’s multibillion-dollar drug Sovaldi, used to cure hepatitis C — is the chief scientific officer of OnCore BioPharma that is set to rebrand itself as Arbutus BioPharma Corp. (NASDAQ: ABUS) starting Monday.
Company officials said the name change “affirms the successful integration” of OnCore BioPharma — which is based at the Pennsylvania Biotechnology Center of Bucks County — and Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) of Vancouver, British Columbia.
Read the full story here.
For more business news, check out pbj.com.
